

Please note the protocols within this list are highly complex and local policies for prescribing and supportive care should be referred to. The list below is advisory and not to be used as a prescribing template.

Chronic Myeloid Leukaemia/MPD treatment		
Please refer to Network guidelines		
REGIMEN	Indication	Drugs
Imatinib	Chronic phase CML or accelerated phase CML (see doses)	Imatinib 400mg od – for chronic phase disease to continue until disease progression or failure to achieve response (refer to guidelines for response criteria) Imatinib 600mg od – for accelerated phase disease or lack of response CP or blast crisis until disease progression or failure to achieve disease response.
Dasatinib	CML chronic accelerated phase – refractory to or intolerant of Imatinib	Dasatinib 100mg od – for patients with chronic phase CML Dasatinib 70mg bd – for accelerated phase disease CML
Nilotinib	CML chronic accelerated phase – refractory to or intolerant of Imatinib	Nilotinib 400mg bd po
Interferon – alpha	CML	For patients intolerant or refractory to TKI and not a candidate for allogeneic SCT. Subcut – dose escalation
Hydroxycarbamide	MPD Cytoreductive agent po	Dose titration according to haematological response